DETAILED ACTION
This action is in response to applicant’s amendment received on September 3rd, 2026.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-8 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-16 of U.S. Patent No. 9,622,874. Although the claims at issue are not identical, they are not patentably distinct from each other because the difference between the invention of claims 1-8 of the current application and the invention of claims 1-16 of the patent lies in the fact that the invention of claims 1-16 of the patent includes more elements and is thus more specific. Thus the invention of claims 1-16 of the patent is in effect a "species" of the "generic" invention of claims 1-8 of the current application. It has been held that the generic invention is “anticipated” by the species. See In re Goodman, 29 USPQ2d 2010 (Fed. Cir. 1993). Since claims 1-8 are anticipated by claims 1-16, claims 1-8 are not patentably distinct from claims 1-16.
Claims 1-8 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-16 of U.S. Patent No. 10,238,501. Although the claims at issue are not identical, they are not patentably distinct from each other because the difference between the invention of claims 1-8 of the current application and the invention of claims 1-16 of the patent lies in the fact that the invention of claims 1-16 of the patent includes more elements and is thus more specific. Thus the invention of claims 1-16 of the patent is in effect a "species" of the "generic" invention of claims 1-8 of the current application. It has been held that the generic invention is “anticipated” by the species. See In re Goodman, 29 USPQ2d 2010 (Fed. Cir. 1993). Since claims 1-8 are anticipated by claims 1-16, claims 1-8 are not patentably distinct from claims 1-16.
Claims 1-8 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-12 of U.S. Patent No. 11,224,521. Although the claims at issue are not identical, they are not patentably distinct from each other because the difference between the invention of claim 1 of the current application and the invention of claims 1-12 of the patent lies in the fact that the invention of claims 1-12 of the patent includes more elements and is thus more specific. Thus the invention of claims 1-12 of the patent is in effect a "species" of the "generic" invention of claims 1-8 of the current application. It has been held that the generic invention is “anticipated” by the species. See In re Goodman, 29 USPQ2d 2010 (Fed. Cir. 1993). Since claims 1-8 are anticipated by claims 1-12, claims 1-8 are not patentably distinct from claims 1-12.
Claims 1-8 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-15 of U.S. Patent No. 12,409,044. Although the claims at issue are not identical, they are not patentably distinct from each other because the difference between the invention of claims 1-8 of the current application and the invention of claims 1-15 of the patent lies in the fact that the invention of claims 1-15 of the patent includes more elements and is thus more specific. Thus the invention of claims 1-15 of the patent is in effect a "species" of the "generic" invention of claims 1-8 of the current application. It has been held that the generic invention is “anticipated” by the species. See In re Goodman, 29 USPQ2d 2010 (Fed. Cir. 1993). Since claims 1-8 are anticipated by claims 1-15, claims 1-8 are not patentably distinct from claims 1-15.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of pre-AIA 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
Claims 1 and 3-8 are rejected under pre-AIA 35 U.S.C. 102(e) as being anticipated by Vestgaarden (U.S. Patent 8,162,981).
Vestgaarden discloses a device (see Figures 1 and 51-54) comprising:
(claim 1) a facet distraction implant (5) including
(claim 1) a top surface
(claim 3) wherein the top surface is a bone facing surface configured to engage a superior aspect of a facet joint upon implantation
(claim 1) a bottom surface
(claim 4) wherein the bottom surface is a bone facing surface configured to engage an inferior aspect of a facet joint upon implantation
(claim 1) a proximal end surface (the surface defining the rim around the opening at end of the implant; see Figure 51)
(claim 1) wherein the proximal end surface if capable of engaging a distal end portion of a delivery device (this is a functional limitation of the proximal end surface since the delivery device is not a part of the invention; the proximal end surface is fully capable of performing the function of engaging the distal end portion of a delivery device)
(claim 1) multiple fixation features (15, 25, and 35) disposed along the top and bottom surfaces
(claim 5) wherein the fixation features are bone contacting features
(claim 6) wherein the bone contacting features are teeth
Vestgaarden discloses a method of using the device comprising:
(claim 1) advancing the device into a patient toward the facet joint (column 2 lines 34-57; see Figures 13-26)
(claim 7) wherein the facet joint is a cervical facet joint (column 5 lines 46-51 describes the shape of the implant being configured to limit motion of cervical facet joints)
(claim 8) wherein the advancing is from a posterior direction relative to the spine of the patient (for example see Figures 13-26; column 4 lines 57-61)
(claim 1) delivering the device into the facet joint (column 2 lines 24-57)
Claim Rejections - 35 USC § 103
The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.
Claim 2 is rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Vestgaarden (U.S. Patent 8,162,981) in view of Blain (U.S. Publication 2005/0177240).
Vestgaarden discloses the invention as claimed (see above) except for the top and bottom surfaces of the facet distraction device being malleable. Blain teaches a method of using a facet distraction device, i.e. a device for altering the space and motion of a facet joint (see abstract), including a top surface and a bottom surface, wherein the facet distraction device is made from a material such that the top and bottom surfaces are malleable in order to conform to the shape of an articular surface of the facet joint under normal anatomical loads (see paragraphs 8, 11, and 12). It would have been obvious to one having ordinary skill in the art at the time the invention was made to provide the invention of Vestgaarden wherein the top and bottom surfaces of the facet distraction device are made from a material such that the surfaces are malleable in view of Blain in order to conform the shape on an articular surface of a facet joint under normal anatomical loads.
Response to Arguments
Applicant's arguments filed September 3rd, 2026 have been fully considered but they are not persuasive. The applicant’s arguments are directed to the new limitations added in the amendment which are discussed in the new grounds of rejection provided above.
Conclusion
The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. See PTO-892 for cited references the examiner felt were relevant.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nicholas Woodall whose telephone number is (571) 272-5204. The examiner can normally be reached on Monday-Friday 8am to 5:30pm.
If attempts to reach the examiner by telephone are unsuccessful, please contact the examiner’s supervisor, Kevin Truong, at (571. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/NICHOLAS W WOODALL/Primary Examiner, Art Unit 3775